Assay to Measure Beta Blocker Adherence
Reason given: Quest Diagnostics terminated study early - did not want to continue to support single-site study
Key facts
- Where
- Akron, United StatesSee the site
Where in United States
- Summa Health SystemAkron, United StatesNo longer taking part
Trial details
- Who runs it
- Summa Health System
- Trial code
- NCT05251974
- Record updated
- 22 November 2023
- Original description
This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.Read full original descriptionShow less
The Effect of Medication Compliance, Verified With Medication Level Testing, on Unplanned Hospital Readmission or Urgent Outpatient Visit in Patients With Acute Decompensated Heart Failure
This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.
Inclusion: Age 18-89; Admitted for primary diagnosis of heart failure with reduced ejection fraction; Prescribed carvedilol or metoprolol succinate for beta blocker therapy; Will be following up at 95 Arch St. Clinic.
Exclusion: Patients with prior heart transplant or a left ventricular assist device; Under age 18/over age 89; Patients that plan to follow up somewhere other than the 95 Arch St. Clinic; Patient is unable to provide consent.